Entecavir (BMS-200475) was synthesized from 4-trimethylsilyl-3-butyn-2-one and acrolein. The key features of its preparation are: (i) a stereoselective boron-aldol reaction to afford the acyclic carbon skeleton of the methylenecylopentane moiety; (ii) its cyclization by a Cp 2 TiCl-catalyzed intramolecular radical addition of an epoxide to an alkyne; and (iii) the coupling with a purine derivative by a 2 Mitsunobu reaction.
Introduction
B-type hepatitis is a global disease. It is one of the most common viral infections worldwide despite an efficient vaccine being available since 1982. According to the World Health Organization (WHO) about two billion people are infected worldwide and 600,000 die every year due to consequences such as cirrhosis of the liver or liver cancer. Hepatitis B can manifest itself in both acute and chronic forms and is especially dangerous in children. About 90% of infants infected during the first year of life develop chronic infections, although this ratio drops to 30-50% in children infected between the ages of one and four. About 25% of adults who become chronically infected during childhood will die from hepatitis Brelated liver cancer or cirrhosis while about 90% of people who become infected during adulthood will recover and be completely free of the virus within six months. About 240 million people are thought to be chronically infected with the disease worldwide. 1 In its chronic form hepatitis B can be treated with interferon or antiviral agents. The most frequently used antiviral agents against hepatitis B virus (HBV) are entecavir (1) Of these, entecavir is considered one of the best choices for the treatment of chronic patients due to its lack of significant adverse effects and the low risk of inducing long-term resistance to the drug. 3 Entecavir (BMS-200475) , first synthesized by Bristol-Myers Squibb, 4 was identified as a potent inhibitor of HBV in vitro (ED 50 = 3 nM) 5 and was later commercialized as Baraclude®. Its patent is due to expire in 2015 in the US and soon afterwards in other countries. In anticipation of the availability of a generic version, a plethora of patent applications has appeared recently. 6,8a-b Most the reported synthetic approaches for the stereoselective construction of the cyclopentane framework are based on transformation of a cyclopentane moiety, 6, 7 and only a few start with an acyclic precursor that is subsequently cyclized. 8 In this paper we disclose a concise synthesis of 1 from acyclic precursors. 9 As shown in Scheme 1, the retrosynthetic analysis of this carbocyclic nucleoside 10 takes advantage of the ability of epoxides to act as effective precursors of radicals. The key step involves the Ti(III)-mediated generation of a β-alkoxy carbon radical 11 from epoxide 4 that can cyclize to a methylene cyclopentane 5 through the cyclic transition state shown in Figure 2 . It is worth noting that the proposed radical cyclization has been reported previously in a failed attempt to prepare 1. Thus, Ziegler 12 prepared epoxide 4b (PG 1 =PG 2 =TBS) from protected D-glucose in 9 steps and reported very good cyclization yields when 4b was treated with 3 equiv of Cp 2 TiCl 2 in the presence of an excess of Zn in THF. Considering these precedents, we implemented an alternative route to epoxides 4 where the key step is an enantioselective acetate aldol addition 13 of methyl ketone 2 to acrolein followed by the in situ reduction of the corresponding β-hydroxy ketone. This approach drastically reduces the number of steps involved and potentially provides more flexibility with respect to the election of protecting groups (PG 1 and PG 2 ).
Results and Discussion
The enantioselective aldol reaction of 4-trimethylsilyl-3-butyn-2-one (2) with acrolein was carried out using (+)-chlorodiisopinocampheylborane ((+)-DIPCl) as source of chirality. 14 As shown in Scheme 2, the in situ reduction of the resulting chelate 15 with LiBH 4 followed by an oxidative work up provided 3a
(PG 1 =PG 2 =H) as a mixture of diols in 66% yield and moderate selectivity (80:20 er, 90:10 syn/anti ratio) after chromatography. It is worth noting that recrystallization from hexanes afforded pure syn diol 3a (98% er, >99% dr) in 37% overall yield. Despite the low yield, this method is very straightforward and allows the skeleton of the cyclization precursor 4 to be constructed from easily available commercial starting materials in a one-pot procedure. 
Scheme 2
Conversion of 3a into the Ziegler's epoxide 4b or its TMS-derivative 6 is very efficient (Scheme 3).
Unfortunately, the cyclization of 4b leads to the methylene cyclopentane 5b (PG 1 =PG 2 =TBS, PG 3 =H, Scheme 1) where the differentiation of TBS ethers would be problematic during the introduction of the nucleobase. On the other hand, our preliminary attempts at the cyclization of epoxide 6 led to the complete degradation of the starting material. With a view to circumventing these limitations we evaluated the cyclization reactions for a series of epoxides of type 4 with different protecting groups (Scheme 1, PG 1 ≠PG 2 
Scheme 3
Preparation of 4 (PG 1 ≠PG 2 ) from 3a or 7a is not trivial in some cases because there is no reliable information in the literature on the selective monoprotection of secondary propargylic alcohols in the presence of secondary allylic ones. In order to establish the viability of the monoprotection reactions, a set of silylations and benzoylations were carried out on these diols. Table 1 summarizes the optimized conditions found for each substrate and highlights the fact that protection of the propargylic position is clearly favored over the protection of the corresponding allylic position. Moderate-to-good yields of the desired monoprotected diol can be achieved while at the same time maintaining the yields of diprotected byproducts below 15%. Yields of the monoprotected allylic alcohol are less than 5%. Based on these results, we attempted to prepare the diprotected epoxides 4g-j (Scheme 4) through selective monoprotection of 3a followed by the removal of the TMS group to afford 7c-e monoalcohols.
The sequence was completed by epoxidation with m-CPBA and final protection of the remaining alcohol. The alternative pathway, in which the epoxidation was the final step was less convenient since the epoxidation of protected allylic alcohols is slow and it is even slower with acetylated allylic alcohols. On the other hand, for the preparation of 4k via 7f removal of the TMS group of 3a to afford diol 7a was the first step in the sequence since this deprotection was not compatible with a benzoate group. Table 1 4c, R = TBS 4d, R = TBDPS 4e, R = TIPS 4f, R = Bz 4g, R = TBS, R' = Ac 4h, R = TBS, R' = TBDPS 4i, R = TBDPS, R' = TBS 4j, R = TIPS, R' = Ac 4k, R = Bz, R' = TBS
Scheme 4
With epoxides 4g-k in hand, we attempted to bring about their Ti(III)-mediated cyclization by treatment with Cp 2 TiCl 2 in the presence of an excess of a metal M such as Zn or Mn (Scheme 5). In this type of reaction the metal reduces Cp 2 TiCl 2 to a Cp 2 TiCl· radical (8). Reaction of 8 with the corresponding epoxide 4 generates the titanocene(IV) β-alkoxy carbon radical 9 that gives rise to a cyclic vinyl radical 9 using an excess of Cp 2 TiCl 2 . Under these conditions, however, we could not reproduce the reported yield. When epoxide 4b was treated with Cp 2 TiCl 2 in the presence of an excess of Zn following the described procedure, the methylene cyclopropane 5b (PG 1 =PG 2 =TBS, PG 3 =H) was obtained with good diastereoselectivity but in a yield of only 30%. 
Scheme 5
Fortunately, yields could be increased to 50% by replacing the aqueous H 2 SO 4 work-up with a treatment with saturated NH 4 Cl (entry 1, Table 2 ). Under these optimized conditions cyclizations of epoxides 4g-k were carried out. The results are summarized in Table 2 and it can be seen that the election of the propargylic alcohol protecting group (R) is critical. TBS provided the best yields (entries 1, 2, and 5) when compared with TIPS and TBDPS (entries 3 and 6) and better selectivity than the benzoyl group (entry 4). In sharp contrast, protection of the allylic alcohol has little effect on yield or selectivity (entries 1, 2, and 5). These results suggested 4b, 4g and 4h to be the most promising candidates for cyclization. We finally chose the transformation of 4g to 5g as the key step of the synthesis because it provided better overall yield from diol 3a and allowed differentiation of the protected alcohols. The Ti-catalytic version of the cyclization was also explored in an attempt to improve the process. In the stoichiometric process 11/12 are cleaved in the final step by treatment with saturated NH 4 Cl. In the catalytic version an alternative proton source is required to cleave 11/12 and regenerate the catalyst.
Gansäuer 16 described the use of collidine hydrochloride as the most convenient reagent for doing so.
After careful optimization of the reaction conditions we were able to carry out the cyclization of 4g to 5g using 20% catalyst and collidine hydrochloride as proton source with excellent selectivity and comparable yields to the stoichiometric version ( The last step in the preparation of the carbocyclic moiety of Entecavir was the protection of the primary hydroxyl group of 5g in the form of a p-nitrobenzoyl ester 5l. The election of this protecting group is important because 5l can be crystallized and purified. By this means chromatographic purifications of intermediates 3a to 5g (which are oils) can be avoided (Scheme 6). 
Scheme 6
Final conversion of 5l to pharmaceutical-grade Entecavir was straightforward. Selective acidic deprotection of the TBS ether followed by Mitsunobu reaction with 2-amino-6-chloropurine 6x led to the chloroderivative 13 that was transformed into protected Entecavir 14 by treatment with formic acid.
Saponification of 14 then gave Entecavir of pharmaceutical grade. Reversal of the order of the last two steps decreased the overall yield and increased the formation of impurities that impeded the crystallization of the final product as did the direct acid hydrolysis of both of the esters and the chloropurine moiety.
Conclusions
A straightforward synthesis of Entecavir was achieved in 11 steps from commercially available starting materials. The cyclopentane skeleton was prepared from acyclic precursors by a boron-aldol reaction and a Ti(III)-catalyzed cyclization of an epoxide to an alkyne as key steps. The carbocylic structure obtained in this way was attached to a purine moiety by a Mitsunobu reaction. It is worth mentioning that the use of the p-nitrobenzoyl group in the final steps allows purification by crystallization thus avoiding chromatography and making the synthesis amenable to scale-up. The selective hydrolysis of the 6-chloropurine unit with formic acid is also essential in order to facilitate the crystallization of the final product.
Experimental Section
All reactions involving moisture-or air-sensitive reagents were performed in oven-dried glassware under N 2 . Chemical shifts (δ) were quoted in parts per million and referenced for 1 H NMR to internal TMS (for CDCl 3 ) or residual solvent peak δ 2.50 ppm (for DMSO-d 6 ). 13 C NMR was referenced to CDCl 3 (δ 77.0 ppm) or DMSO-d 6 (δ 39.5 ppm). Column chromatography was performed on silica gel (Merck 230-400 mesh). HRMS analyses were recorded on a LC/MSD-TOF mass spectrometer.
(3S,5R)-7-(Trimethylsilyl)hept-1-en-6-yne-3,5-diol (3a). NEt 3 (11.60 mL, 85 mmol) was added to a stirred solution of (+)-DIPCl (90-105%) (25.000 g, 78 mmol) in anhydrous THF (40 mL) under N 2 at 0 ºC. 4-Trimethylsilyl-3-butyn-2-one (98%, 9.78 g, 70 mmol) was added dropwise and the mixture was stirred for 2 h at -5 ºC-0 ºC. The solution was cooled to -78 ºC and a solution of acrolein (90%, 7.62 mL, 103 mmol) in anhydrous THF (20 mL) was added slowly and the mixture was stirred for 1 h at -78 ºC. A 2 M solution of LiBH 4 in hexanes (53 mL, 106 mmol) was added slowly and the mixture was stirred for a further 1 h at -78 ºC. After careful quenching with saturated NH 4 Cl (40 mL) at -78 ºC the mixture was allowed to warm to rt over 30 min. After partitioning between H 2 O (40 mL) and MTBE (90 mL) the aqueous layer was extracted with MTBE (25 mL). The organic phases were combined and dried (MgSO 4 ). Solvent removal afforded a pale yellow oil (62 g). THF:H 2 O (3:1, 80 mL) was added under N 2 at rt followed by NaOAc (4.40 g, 54 mmol) and the mixture was cooled to 0 ºC. H 2 O 2 (30%, 30 mL, 5 equiv) was added dropwise over 10 min and the mixture was stirred for a further 10 min at 0 ºC and 30 min at rt. After cooling to 0 ºC a saturated solution of Na 2 S 2 O 3 (30 mL) was added slowly and the mixture was stirred for 10 min at 0 ºC and 15 min at rt. H 2 O (20 mL) and MTBE (35 mL) were added and the organic phase was decanted. The aqueous layer was extracted with MTBE (10 mL 
(3S,5R)-3,5-Bis(tert-butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yne (3b). A solution of
TBSCl (0.800 g, 5.30 mmol) in anhydrous CH 2 Cl 2 (5 mL) was added dropwise to a solution of diol 3a (0.500 g, 2.52 mmol) and imidazole (0.377 g, 5.54 mmol) in anhydrous CH 2 Cl 2 (5 mL) at 0 ºC under N 2 .
The mixture was allowed to warm to rt and was stirred for 15 h. A 22% solution of NH 4 Cl (5 mL) was added slowly and the mixture was stirred for 10 min. The mixture was partitioned and the aqueous phase was extracted with CH 2 Cl 2 (5 mL). The organic phase was dried (MgSO 4 ) and the solvent was removed affording an oil that was purified by flash chromatography (silica gel, hexanes-AcOEt 95:5) to give 3, 114.4, 107.4, 89.5, 71.3, 61.3, 46.9, 26.0, 25.9, 18.4, 18.3, 0.0, -4.1, -4.3, -4.8, -4 (3S,5R)-5-(tert-Butyldiphenylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol (3d). TBDPSCl (1.57 mL, 6.10 mmol) was added dropwise to a solution of diol 3a (1.000 g, 5.04 mmol) and imidazole (0.481 g, 7.06 mmol) in anhydrous THF (9.5 mL) at 0 ºC under N 2 , and the mixture was allowed to warm to rt and was stirred for 5 h. A 22% solution of NH 4 Cl (5 mL) was added slowly and the mixture was stirred for 10 min. The mixture was partitioned and the organic phase was dried (MgSO 4 ), and the solvent was removed affording an oil that was purified by flash chromatography [silica gel, hexanes-AcOEt, from 95:5 to 90:10 (gradient elution)] to give 1.363 g (62%) of the title compound (3d) as a pale yellow oil.
[α] D 25 +62. 2, 136.0, 134.9, 133.6, 133.3, 130.0, 129.8, 129.7, 127.8, 127.7, 127.5, 114.5, 106.2, 91.3, 70.6, 62.8, 45.2, 27.0, 26.7, 19.4, -0.4 3, 114.4, 85.4, 72.9, 71.1, 60.6, 47.2, 26.0, 25.9, 18.4, 18.3, -4.1, -4.4, -4.8, -4.9 2, 136.0, 133.3, 133.3, 130.4, 129.9, 127.8, 127.6, 114.6, 84.5, 74.2, 70.3, 62.1, 45.3, 27.0, 19.4 
(1S,3R)-1,3-Bis(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)-5-(trimethylsilyl)pent-4-yne (6).
A solution of 3b (0.900 g, 2.11 mmol) in anhydrous CH 2 Cl 2 (5 mL) was added to a suspension of m-CPBA (77%, 1.417 g, 6.32 mmol) in anhydrous CH 2 Cl 2 (10 mL) at rt under N 2 and the mixture was stirred at rt for 15 h. The mixture was filtered and the organic phase was washed with saturated Na 2 S 2 O 3 (5 mL), saturated NaHCO 3 (10 mL), dried (MgSO 4 ) and the solvent was removed to give the title compound (6) as a yellow oil (0.853 g, 91% (CDCl 3 , 101 MHz): δ 84. 5, 84.4, 73.6, 73.5, 69.7, 68.2, 61.7, 61.3, 55.2, 54.3, 44.9, 44.4, 42.4, 41.9, 25 2, 130.10, 130.1, 130.0, 127.9, 127.8, 127.6, 127.5, 84.1, 84.1, 74.3, 74.2, 68.8, 66.7, 61.9, 61.7, 55.2, 54.4, 45.0, 43.9, 42.7, 41.7, 27.0, 19.4 7, 84.6, 73.6, 73.6, 69.5, 67.5, 61.5, 61.2, 55.4, 54.4, 45.0, 44.2, 42.8, 42.1, 18.1, 18.1, 12.4, 12.3 133.5, 133.4, 129.9, 129.9, 129.6, 129.6, 128.6, 128.5, 80.7, 80.6, 74.9, 74.8, 68.5, 65.9, 62.1, 62.0, 55.1, 54.2, 45.1, 43.7, 39.3, 38.4 1, 85.1, 74.5, 74.4, 72.0, 70.9, 60.8, 54.1, 53.2, 46.3, 40.9, 40.7, 26.8, 22.1, 22.0, 19.2, -3.5, -4 2, 136.1, 136.1, 136.0, 134.0, 133.8, 133.7, 133.4, 130.0, 129.9, 129.8, 129.7, 127.8, 127.7, 127.7, 127.5, 85.1, 84.7, 73.1, 73.0, 72.9, 71.3, 60.1, 60.0, 55.6, 54.5, 46.5, 45.2, 44.6, 43.5, 27.2, 27.1, 25.9, 25.8, 19.6, 19.5, 18.3, 18.2, -4.4, -4.5, -4.9 (s, 2H), 0.14 (s, 1H), 0.11 (s, 1H), 0.04 (s, 2H). 13 C NMR (CDCl 3 , 101 MHz): δ 136. 2, 136.1, 135.9, 135.9, 133.5, 133.4, 130.0, 129.9, 129.8, 129.7, 127.8, 127.8, 127.6, 127.5, 84.5, 84.4, 74.1, 74.0, 72.4, 68.6, 61.8, 56.0, 54.7, 45.0, 44.7, 43.6, 43.0, 27.0, 25.9, 25.9, 19.4, 18.1, 18.1, -4.4, -4.3, -5.1, -5.3 . and the mixture was allowed to warm to rt and stirred for 1 h. Saturated NH 4 Cl (5 mL) was added slowly and the mixture was stirred for 10 min. After partitioning the aqueous phase was extracted with CH 2 Cl 2 (5 mL) and the organic phases were combined and washed with saturated NaHCO 3 (2 × 5 mL).
(1S,3R)-3-(tert-Butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol (4c). A suspension of m-

(3R,5S)-5-Hydroxy-5-(oxiran-2-yl)pent-1-yn-3-yl benzoate (4f
HRMS (ESI)
The combined organic phases were dried (MgSO 4 ), and solvent removal gave the title compound (4j) as a yellow oil (0.508 g, 90% 1, 84.1, 73.5, 73.4, 70.9, 69.8, 60.0, 59.9, 53.2, 52.2, 45.3, 40.2, 39.7, 21.0, 20.9, 18.1, 18.0, 17.8, 12.4, 12.3, 12.2 3, 165.2, 133.4, 133.4, 129.9, 129.8, 129.7, 128.6, 128.5, 80.8, 74.8, 74.7, 72.0, 68.6, 62.1, 61.8, 55.7, 54.5, 45.2, 45.0, 40.1, 39.6, 26.0, 25.9, 18.2, -4.2, -4.3, -4.9, -5 
(3R,5S)-5-(tert-Butyldimethylsilyloxy)-5-(oxiran-2-yl)pent-1-yn-3-yl benzoate (4k
General procedure for non-catalytic 5-exo cyclization
Strictly deoxygenated anhydrous THF (76 mL) was added to a mixture of Cp 2 TiCl 2 (1.711 g, 6.87 mmol) and activated Zn powder (1.800 g, 27.48 mmol) under N 2 and the suspension was stirred at rt until it turned lime green. This suspension was then added slowly to a solution of 4b (0.850 g, 2.29 mmol) over 3 h and the mixture was stirred for 15 h at rt. A 22% solution of NH 4 Cl (60 mL) was added slowly and the mixture was stirred for 2 h, filtered and the solvent was removed. AcOEt (100 mL) was added and the mixture was stirred for 10 min. The mixture was partitioned and the aqueous phase was extracted with AcOEt (2 × 50 mL). The combined organic phases were dried (MgSO 4 ) and the solvent was removed. The resulting oily residue was purified by flash chromatography [silica gel, hexanes-AcOEt, from 95:5 to 80:20 (gradient elution)] to give the title compound as a pale yellow oil (0.424 g, 50%). MHz): δ 152. 1, 108.4, 72.4, 71.0, 63.0, 53.2, 43.9, 26.0, 25.9, 18.4, 18.1, -4.1, -4.4, -4.6, -4.7 9, 151.7, 109.0, 73.5, 72.7, 63.7, 51.0, 40.5, 25.9, 21.3, 18.3, -4.5, -4.7 4, 136.0, 134.3, 134.0, 131.0, 130.0, 129.9, 128.0, 127.9, 127.8, 126.7, 108.2, 72.4, 71.6, 62.7, 53.6, 43.7, 27.1, 26.0, 19.3, 18.3, -4.5, -4.7 7, 133.1, 130.3, 129.8, 128.5, 112.0, 74.2, 72.2, 62.5, 53.5, 40.5, 25.9, 18.0, -4.3, -4.8 
((1R,3R,5S)-3,5-Bis(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methanol (5b
Catalytic 5-exo cyclization of 4g
Strictly deoxygenated anhydrous THF (15 mL) was added to a mixture of IrCl(CO)(PPh 3 ) 2 (0.260 g, 0.34 mmol) and manganese powder (0.368 g, 6.70 mmol). A solution of 2,4,6-collidine (3.5 mL, 26.8 mmol) and 4g (1.000 g, 3.35 mmol) in strictly deoxygenated anhydrous THF (22 mL) was added at rt.
TMSCl (1.7 mL, 13.4 mmol) was added followed by a solution of Cp 2 TiCl 2 (0.167 g, 0.67 mmol) in strictly deoxygenated anhydrous THF (12 mL) and the mixture was stirred for 4 h under H 2 (4 bar) at rt.
Water (5 mL) was added and the mixture was stirred for 10 min and filtered through Celite®. The pad was washed with MTBE (20 mL) and the organic phases were combined and acidified to pH=2 with 2 M HCl. The mixture was stirred for 15 min and the phases were separated. The organic phase was washed with H 2 O (20 mL) and dried (Na 2 SO 4 ). The solvent was removed and the resulting oily residue was purified by flash chromatography [silica gel, hexanes-AcOEt, from 90:10 to 60:40 (gradient elution)] to give the title compound (5g) as a pale yellow oil (0.582 g, 58%). MHz): δ 170. 9, 164.6, 150.7, 150.5, 135.5, 130.8, 123.7, 110.1, 73.2, 72.5, 66.3, 46.9, 40.5, 25.9, 21.2, 18.3, -4.5, -4.6 6, 164.6, 151.3, 150.8, 135.4, 130.8, 123.8, 112.3, 74.8, 73.2, 65.9, 47.9, 40.1, 21.3 ((1R,3S,5S)-5-Acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate (13). A mixture of 2-amino-6-chloropurine (7.380 g, 43 .54 mmol) and triphenylphosphine (11.400 g, 43.54 mmol) in anhydrous THF (927 mL) at rt under N 2 was stirred for dropwise and the mixture was stirred for 10 min. A solution of 5m (7.300 g, 21 .77 mmol) in anhydrous THF (160 mL) was added over 1 h. The mixture was stirred for 3 h at -10 ºC and was then allowed to warm to rt, filtered and the residue was washed with THF (109 mL). The solvent was removed and the resulting oily residue was purified by crystallization from isopropanol (440 mL) to afford the title compound as a pale yellow solid (6.510 g, 61% 3, 165.0, 158.9, 153.1, 151.8, 150.8, 146.2, 141.9, 135.2, 130.9, 125.9, 123.8, 113.6, 74.6, 65.9, 57.4, 48.7, 35.5, 21.3 
((1R,3R,5S)-5-Acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-nitrobenzoate (5l
((1R,3S,5S)-5-Acetoxy-3-(2-amino-6-oxo-1H-purin-9(6H)-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate (14)
. A solution of 13 (6.300 g, 12.94 mmol) in formic acid 80% (126 mL) at 50 ºC under N 2 was stirred for 9 h. The solvent was removed, H 2 O (72 mL) was added and the suspension was stirred for 18 h at rt. The suspension was filtered and the solid was dried to afford the title compound (14) as a yellow solid (5.590 g, 92% 9, 164.3, 156.8, 153.5, 151.2, 150.3, 147.8, 136.1, 135.1, 130.7, 123.9, 116.5, 111.2, 74.1, 65.6, 55.2, 47.8, 35.2, 21.0 
2-Amino-9-((1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-methylenecyclopentyl)-1H-purin-6(9H)-one monohydrate (1).
A solution of MeONa (30%, 4.10 mL, 22.20 mmol) was added dropwise to a solution of 14 (5.200 g, 11.10 mmol) in anhydrous MeOH (40 mL) at rt under N 2 . The mixture was stirred for 30 min at rt and cooled to 0 ºC. MTBE (52 mL) was added and the mixture was neutralized (pH=7) with HCl. The phases were separated and the aqueous layer was extracted with MTBE (50 mL).
The volume of the aqueous phase was reduced to 45 mL by distillation. The suspension was heated at 85 ºC and was slowly cooled to rt and stirred for 15 h. After filtration the isolated solid was dried under vacuum to afford the title compound (1) 
